BNTX - BioNTech's Acquisition Of Neon Highlights Potential Use Of Neoantigens For Cancer Treatment
BioNTech (BNTX) recently announced that it had acquired Neon Therapeutics (NTGN) for $67 million in an all-stock deal. The acquisition of this biotech was a wise one, because personalized antigens (neoantigens) can potentially become a more profound way of treating cancer patients. Besides the acquisition of Neon, BioNTech had already established 3 or more big partnership deals with well-known pharmaceutical companies. The company already has translational science with its approach of combining messenger RNA (mRNA) together with cell therapies like T-cell receptors (TCRs) or Chimeric antigen receptors (CAR-Ts) to improve efficacy